Biopharmaceutical drug discovery using novel protein scaffolds

Current Opinion in Biotechnology

Volumn 17, Issue 6, 2006, Pages 653-658

  Gill, Davinder S ^a   Damle, Nitin K ^b  

^a PFIZER INC   (United States)

^b WYETH RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODIES; DRUG PRODUCTS; MOLECULAR STRUCTURE;

ANTIBODY THERAPEUTIC STRATEGIES; BIOPHARMACEUTICAL DRUG PRODUCTS; PROTEIN SCAFFOLD TECHNOLOGIES; PROTEIN THERAPEUTICS;

PROTEINS;

ADNECTIN; ANGIOCEPT; ANKYRIN; ANTICALIN; CD20 ANTIBODY; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; LIPOCALIN; MONOCLONAL ANTIBODY; PROTEIN A; PROTEIN DERIVATIVE; REV 131 PROTEIN; SCAFFOLD PROTEIN; STEROID; TETRANECTIN; TRU 015; UNCLASSIFIED DRUG;

B LYMPHOCYTE; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DRUG MANUFACTURE; HAY FEVER; HUMAN; LYMPHOCYTOPENIA; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; REVIEW; RHEUMATOID ARTHRITIS;

BIOPHARMACEUTICS; DRUG DESIGN; DRUG EVALUATION, PRECLINICAL; PROTEINS;

EID: 33751347582     PISSN: 09581669     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.copbio.2006.10.003     Document Type: Review

References (24)

1. Guide to Biotechnology: Biotechnology Industry Organization 2006; p. 3.
2. Schmidt E. Crystal gazing: biotech's financial outlook: the biotech analyst's view. Nat Biotechnol 24 (2006) 261-262
3. Monoclonal Antibody Therapeutics - Current Market Dynamics & Future Outlook. AS Insights Publishers, June 1; 2004.
4. Carreyrou J, Anand G: Wary of backlash, cancer-drug makers weight price limits. Wall Street Journal, May 10, 2006, p. B1.
5. Holliger P., and Hudson P.J. Engineered antibody fragments and the rise of single domains. Nat Biotechnol 23 (2005) 1126-1136
6. Ward E.S., Gussow D., Griffiths A.D., Jones P.T., and Winter G. Binding activities of a repertoire of single immunoglobulin variable domains secreted from Escherichia coli. Nature 341 (1989) 544-546
7. Hamers-Casterman C., Atarhouch T., Muyldermans S., Robinson G., Hamers C., Songa E.B., Bendahman N., and Hamers R. Naturally occurring antibodies devoid of light chains. Nature 363 (1993) 446-448
8. Spinelli S., Frenken L., de Bourgeoise D., de Ron L., Bos W., Verrip T., Anguille C., Cambillau C., and Tegoni M. The crystal structure of a llama heavy chain variable domain. Nat Struct Biol 3 (1996) 752-757
9. Holt L.J., Herring C., Jespers L.S., Woolven B.P., and Tomlinson I.M. Domain antibodies: proteins for therapy. Trends Biotechnol 21 (2003) 484-490
10. H domains with improved protein stability. Protein Eng 9 (1996) 531-537
11. Haan K, Maggos C: The protein engineers. Biocentury Jan 26, 2004.
12. Kastrup J.S., Nielsen B.B., Rasmussen H., Holtet T.L., Graversen J.H., Etzerodt M., Thogersen H.C., and Larsen I.K. Structure of the C-type lectin carbohydrate recognition domain of human tetranectin. Acta Crystallogr D Biol Crystallogr 54 (1998) 757-766
13. Xu L., Aha P., Gu K., Kuimelis R.G., Kurz M., Lam T., Lim A.C., Liu H., Lohse P.A., Sun L., et al. Directed evolution of high-affinity antibody mimics using mRNA display. Chem Biol 9 (2002) 933-942
14. Getmanova E.V., Chen Y., Bloom L., Gokemeijer J., Shamah S., Warikoo V., Wang J., Ling V., and Sun L. Antagonists to human and mouse vascular endothelial growth factor receptor 2 generated by directed protein evolution in vitro. Chem Biol 13 (2006) 549-556. Describes the use of the 10FN3 scaffold to derive potent inhibitors of VEGFR2, one of which is in early clinical development. The power of directed evolution in isolating hits that are cross-reactive between human and rodent species is described.
15. North C.L., and Blacklow S.C. Structural independence of ligand-binding modules five and six of the LDL receptor. Biochemistry 38 (1999) 3926-3935
16. Silverman J., Liu Q., Bakker A., To W., Duguay A., Alba B.M., Smith R., Rivas A., Li P., Le H., et al. Multivalent avimer proteins evolved by exon shuffling of a family of human receptor domains. Nat Biotechnol 23 (2005) 1556-1561. Reports a completely novel approach that uses A-domains to built multimers of protein antagonists. These proteins have several properties of classical protein therapeutics, but have the additional advantage of high bacterial expression and good thermal stability. An example of avimers against interleukin-6 is described.
17. Schlehuber S., and Skerra A. Lipocalins in drug discovery: from natural ligand-binding proteins to 'anticalins'. Drug Discov Today 10 (2005) 23-33
18. Vogt M., and Skerra A. Construction of an artificial receptor protein ('anticalin') based on the human apolipoprotein D. ChemBioChem 5 (2004) 191-199
19. Sedgwick S.G., and Smerdon S.J. The ankyrin repeat: a diversity of interactions on a common structural framework. Trends Biochem Sci 24 (1999) 311-316
20. Binz H.K., Amstutz P., Kohl A., Stumpp M.T., Briand C., Forrer P., Grutter M.G., and Pluckthun A. High-affinity binders selected from designed ankyrin repeat protein libraries. Nat Biotechnol 22 (2004) 575-582. This paper demonstrated another novel approach of using ankyrin repeat proteins as scaffolds. Because these proteins contain no cysteines, they can be efficiently expressed in the cytoplasm of bacteria. Thus, intracellular targets such as kinases can be targeted with high specificity.
21. Lu D., Zhang H., Koo H., Tonra J., Balderes P., Prewett M., Corcoran E., Mangalampalli V., Bassi R., Anselma D., et al. A fully human recombinant IgG-like bispecific antibody to both the epidermal growth factor receptor and the insulin-like growth factor receptor for enhanced antitumor activity. J Biol Chem 280 (2005) 19665-19672
22. Lu D., Zhang H., Ludwig D., Persaud A., Jimenez X., Burtrum D., Balderes P., Liu M., Bohlen P., Witte L., and Zhu Z. Simultaneous blockade of both the epidermal growth factor receptor and the insulin-like growth factor receptor signaling pathways in cancer cells with a fully human recombinant bispecific antibody. J Biol Chem 279 (2004) 2856-2865
23. Burge DJ, Bookbinder SA, Kivitz A J, Fleischmann RM, Shu C, Bannink J, Barone D: Phase 1 study of TRU-015, a CD-20 directed small modular immunopharmaceutical protein therapeutic, in subjects with rheumatoid arthritis. European League Against Rheumatism 2006 Amsterdam, June 24-26. Annals of the Rheumatic Diseases 2006, 65(Suppl 2):180. Early clinical success with the anti-CD20 SMIP is demonstrated. This novel protein scaffold is safe and well-tolerated in man. The pharmacokinetic profile looks good, which could allow weekly or bimonthly dosing in rheumatoid arthritis patients.
24. Macilwain C. Ticking the right boxes. Nature 439 (2006) 553